The Latest Cardiac and Vascular News
Korean nationwide cohort study shows increased complications for both mothers and newborns in deliveries following uterine artery embolization SEOUL, South Korea, Sept. 23, 2024 /PRNewswire/ — Postpartum hemorrhage (PPH) is a serious condition where a woman experiences significant blood…
TAMPA, Fla. and WAYNE, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) — NewVue, a leader in cloud-native radiology workflow solutions, and Konica Minolta Healthcare Americas, Inc., a leading provider of medical diagnostic imaging and healthcare information technology, announce a strategic partner agreement. This partnership allows Konica Minolta to offer NewVue’s innovative EmpowerSuite Radiology Workflow Orchestrator and Command Center to its extensive network of healthcare customers across the US, integrating seamlessly with Konica Minolta’s Exa® Platform to enhance radiology workflows. EmpowerSuite is a key component of Konica Minolta’s enterprise imaging portfolio.
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass. (September 16, 2024) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, today announced that it has received certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres® […]
WALLINGFORD, Conn. and TAMPA, Fla., Sept. 11, 2024 /PRNewswire/ — InsiteOne, NewVue.AI, and RADPAIR are thrilled to announce a groundbreaking strategic contract with Aligned Radiology, a leading teleradiology provider. This collaboration combines advanced AI-driven workflow…
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.
Allegheny Health Network’s (AHN) Allegheny Valley Hospital (AVH) has completed a $12 million expansion and renovation of its imaging and radiology department. The new 8,000-square-foot imaging center, located on the ground floor of AVH, offers state-of-the-art imaging technologies and…
Harrison.rad.1 significantly outperforms other major models on radiology tasks The new model is being made accessible to select healthcare professionals and regulators to open up the conversation on responsible use of AI in healthcare SYDNEY, Sept. 4, 2024 /PRNewswire/ — Healthcare AI…
Niagara Falls, NY, Aug. 26, 2024 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce the sale of Positron’s NeuSight PET-CT 64 slice scanner to a recognized leader in preventive, invasive and interventional cardiovascular services.
WOBURN, Mass., Aug. 5, 2024 /PRNewswire/ — Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer. SIR-Spheres® FLEXdose SELECT Delivery Program offers unparalleled flexibility by […]
BURLINGAME, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, today announced that its investigational diagnostic imaging agent drug, 124I-evuzamitide (AT-01), has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging in patients with suspected or known cardiac amyloidosis. FDA granted BTD for 124I-evuzamitide (AT-01) based on clinical data from Attralus-sponsored and investigator-initiated studies evaluating the use of 124I-evuzamitide in patients with cardiac amyloidosis, representing experience in more than 200 trial participants.
